Auxano Advisors LLC Boosts Stock Position in Novo Nordisk A/S (NYSE:NVO)

Auxano Advisors LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,443 shares of the company’s stock after buying an additional 429 shares during the period. Novo Nordisk A/S comprises 0.7% of Auxano Advisors LLC’s investment portfolio, making the stock its 23rd largest position. Auxano Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,619,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of NVO. DAVENPORT & Co LLC boosted its position in Novo Nordisk A/S by 75.1% during the fourth quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company’s stock valued at $90,477,000 after buying an additional 451,641 shares during the period. Wellington Management Group LLP purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at about $42,017,000. DSM Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company’s stock valued at $172,678,000 after acquiring an additional 286,912 shares during the period. World Investment Advisors LLC grew its position in Novo Nordisk A/S by 2,655.9% during the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after acquiring an additional 270,234 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Novo Nordisk A/S by 53.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 729,965 shares of the company’s stock worth $63,183,000 after purchasing an additional 254,475 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 1.6 %

NYSE:NVO opened at $90.68 on Monday. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $84.82 and a 200-day moving average price of $106.52. The stock has a market cap of $406.91 billion, a price-to-earnings ratio of 27.56, a P/E/G ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is 47.72%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, BMO Capital Markets reduced their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.